Floatz logo

PCV 13

Small Lymphocytic Lymphoma

Massachusetts General HospitalvaccinePhase 2Dormant
B
63/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
53/ 100
Competitive Position
81/ 100

Competitive context

9 Active assets in the Small Lymphocytic Lymphoma cohort.

Asset / SponsorPhaseRating
PREDNISONE TABLETS
AstraZeneca
Phase 3BBB
(+)-VINCRISTINE
AstraZeneca
Phase 3BB
Eloxatin
City of Hope Medical Center
Phase 2BB
Epcoritamab
City of Hope Medical Center
Phase 2BB
Imexon
University of Rochester
Phase 2B

View all 18 →

Same molecule, other indications

PCV 13 is also rated in:

pneumococcal infectionDormant
BB
Indicative ·
64 / 100
View asset →
relapsing-remitting multiple sclerosisDormant
B
Indicative ·
60 / 100
View asset →
chronic lymphocytic leukemia/small lymphocytic lymphomaDormant
B
Indicative ·
58 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →